[en] Signalling pathways inhibition hold promise as therapeutic targets in osteoarthritis but safety concern may limit their use to the more sevre form of the disease.
Disciplines :
Rheumatology
Author, co-author :
Henrotin, Yves ; Université de Liège - ULiège > Département des sciences de la motricité > Unité de recherche sur l'os et le cartillage (U.R.O.C.)
Language :
English
Title :
Does signalling pathways inhibition hold therapeutic promise for osteoarthritis?
Loeser R.F., Goldring S.R., Scanzello C.R., Goldring M.B. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum 2012, 64:1697-1707.
Saito T., Kawaguchi H. HIF-2alpha as a possible therapeutic target of osteoarthritis. Osteoarthritis Cartilage 2010, 18:1552-1556.
Feist E., Burmester G.R. Small molecules targeting JAKs - a new approach in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2013, 52:1352-1357.
Akasaki Y., Hasegawa A., Saito M., et al. Dysregulated FOXO transcription factors in articular cartilage in aging and osteoarthritis. Osteoarthritis Cartilage 2014, 22:162-170.
Lories R.J., Corr M., Lane N.E. To Wnt or not to Wnt: the bone and joint health dilemma. Nat Rev Rheumatol 2013, 9:328-339.
Yusuf E., Nelissen R.G., Ioan-Facsinay A., et al. Association between weight or body mass index and hand osteoarthritis: a systematic review. Ann Rheum Dis 2010, 69:761-765.
Conde J., Scotece M., Lopez V., et al. Adipokines: novel players in rheumatic diseases. Discov Med 2013, 15:73-83.
Sellam J., Berenbaum F. Is osteoarthritis a metabolic disease?. Joint Bone Spine 2013, 80:568-573.
Puenpatom R.A., Victor T.W. Increased prevalence of metabolic syndrome in individuals with osteoarthritis: an analysis of NHANES III data. Postgrad Med 2009, 121:9-20.
Yoshimura N., Muraki S., Oka H., et al. Accumulation of metabolic risk factors such as overweight, hypertension, dyslipidaemia, and impaired glucose tolerance raises the risk of occurrence and progression of knee osteoarthritis: a 3-year follow-up of the ROAD study. Osteoarthritis Cartilage 2012, 20:1217-1226.
Zhang W., Nuki G., Moskowitz R.W., et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010, 18:476-499.
Chevalier X., Eymard F., Richette P. Biologic agents in osteoarthritis: hopes and disappointments. Nat Rev Rheumatol 2013, 9:400-410.
Coombs J.H., Bloom B.J., Breedveld F.C., et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2010, 69:413-416.
Kremer J.M., Cohen S., Wilkinson B.E., et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 2012, 64:970-981.
Yano F., Hojo H., Ohba S., et al. A novel disease-modifying osteoarthritis drug candidate targeting Runx1. Ann Rheum Dis 2013, 72:748-753.
